Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.

  • Revenue in GBP (TTM)30.33bn
  • Net income in GBP4.93bn
  • Incorporated1999
  • Employees70.21k
  • Location
    GSK plc980 Great West RoadBRENTFORD TW8 9GSUnited KingdomGBR
  • Phone+44 208 047 5000
  • Fax+44 208 047 7807
  • Websitehttps://www.gsk.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
GSK:LSE since
announced
Transaction
value
Aiolos Bio IncDeal completed09 Jan 202409 Jan 2024Deal completed10.30%1.40bn
BELLUS Health IncDeal completed18 Apr 202318 Apr 2023Deal completed13.02%1.87bn
Data delayed at least 20 minutes, as of Mar 28 2024 16:38 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Genmab A/S1.89bn499.95m15.83bn2.20k31.554.31--8.3666.0566.05249.95483.850.5037--3.097,474,592.0013.3117.4314.2518.5955.82--26.4235.8713.32--0.0238--13.5740.35-20.1824.21-4.66--
argenx SE970.32m-233.46m18.71bn1.15k--5.76--19.28-4.75-4.7519.8763.940.31950.43733.72986,714.40-7.69-17.65-8.49-19.7990.39---24.06-97.729.01--0.0049--198.56117.2558.42--122.32--
UCB SA4.50bn293.82m18.95bn9.08k64.612.4021.404.211.761.7626.9147.300.33451.764.63578,223.102.185.032.676.2867.5072.216.5312.660.92243.140.252936.44-4.802.54-18.33-15.41-1.512.36
Bayer AG40.81bn-2.52bn23.92bn99.72k--0.8483.740.5861-2.99-2.9948.4933.520.39511.434.85477,693.20-2.44-1.79-3.34-2.3858.5459.02-6.18-4.800.80153.400.5764---6.115.33-170.87--1.19-47.66
HALEON PLC11.30bn1.05bn30.14bn24.00k29.241.8449.082.670.11280.11281.221.800.32823.155.76470,916.703.23--3.73--61.59--9.83--0.73497.370.3611--4.09---1.04------
Lonza Group AG5.88bn572.51m34.90bn17.90k60.294.0929.275.948.888.8890.98130.870.39282.804.84--3.835.074.646.2129.0039.149.7514.521.2012.350.227530.587.943.92-46.17-0.030623.957.78
Merck KGaA17.98bn2.42bn59.66bn62.91k24.662.6115.093.326.506.5048.2761.360.43271.865.03333,709.505.845.647.207.2759.0361.8613.4912.970.891632.810.26949.26-5.577.19-15.0921.4014.7711.97
GSK plc30.33bn4.93bn70.68bn70.21k14.185.188.662.331.201.207.393.290.50911.574.20431,949.008.916.7413.9110.7172.4270.2917.5016.930.62410.990.584879.553.42-0.32215.797.105.47-10.32
Sanofi SA39.78bn4.63bn99.42bn87.99k21.341.5515.032.504.304.3037.0459.170.36691.535.51527,808.704.385.875.437.1669.3568.7811.9516.900.867566.190.198660.512.325.42-35.494.578.874.14
Roche Holding AG51.40bn10.07bn161.87bn103.61k15.866.1711.693.1514.3014.3073.0336.770.65741.915.19566,729.4013.8416.1220.8425.2473.3971.4821.0522.981.0420.770.467658.80-7.210.6494-7.431.9010.011.99
Novartis AG36.91bn6.78bn166.13bn76.06k23.294.2012.294.503.726.4620.1920.630.42931.846.15554,408.407.898.5310.5711.2374.2472.9318.3722.680.93113.160.360567.207.570.277941.64-7.710.78086.19
AstraZeneca plc36.25bn4.71bn166.52bn89.90k35.595.3818.554.593.023.0223.2119.980.46371.594.05403,208.206.033.348.474.6182.3979.6413.017.690.64276.340.4222143.063.2915.7181.1122.5422.471.10
Novo Nordisk A/S26.68bn9.61bn347.78bn63.37k47.3336.8733.2813.0318.6218.6251.6823.900.83591.274.033,665,157.0030.1229.1763.1258.6284.6083.9336.0333.550.6356--0.202250.1331.2615.7450.7116.7225.6718.20
Data as of Mar 28 2024. Currency figures normalised to GSK plc's reporting currency: UK Pound GBX

Institutional shareholders

19.75%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 01 Mar 2024155.49m3.78%
BlackRock Fund Advisorsas of 01 Mar 2024119.64m2.91%
Dodge & Coxas of 23 Feb 202499.38m2.41%
Norges Bank Investment Managementas of 01 Mar 202488.92m2.16%
Schroder Investment Management Ltd.as of 01 Mar 202470.63m1.72%
Legal & General Investment Management Ltd.as of 01 Mar 202466.63m1.62%
BlackRock Advisors (UK) Ltd.as of 01 Mar 202462.44m1.52%
Silchester International Investors LLPas of 01 Mar 202454.81m1.33%
SSgA Funds Management, Inc.as of 01 Mar 202448.11m1.17%
Mondrian Investment Partners Ltd.as of 01 Mar 202446.97m1.14%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.